Sentences with phrase «pharma patent»

Competition Bureau Issues Draft Updated IP Enforcement Guidelines Addressing Pharma Patent Litigation Settlements, Standard Setting and Patent Trolls → Read

Chicago, IL About Blog Patent Docs is a weblog authored by patent practitioners, which focuses on biotech / pharma patent law, including reports on changes in USPTO rules and procedures, recent court decisions, newly filed patent litigation, and recently issued patents.

Related Pharma Patent Blogs Submit Your Blog SUBMIT BLOG Pharma Blogs 1.

The Best Pharma Patent blogs from thousands of top Pharma blogs in our index using search and social metrics.

Leesburg, VA About Blog Find updates on Pharma Patent from IPWatchdog.com.

This is the most comprehensive list of best Pharma Patent blogs on the internet and I'm honoured to have you as part of this!

IP lawyer Andrew Skodyn of Lenczner Slaght Royce Smith Griffin LLP agrees it does appear some of the pharma patent changes that had been talked about are coming to pass.

Chicago, IL About Blog Patent Docs is a weblog authored by patent practitioners, which focuses on biotech / pharma patent law, including reports on changes in USPTO rules and procedures, recent court decisions, newly filed patent litigation, and recently issued patents.

Chicago, IL About Blog Patent Docs is a weblog authored by patent practitioners, which focuses on biotech / pharma patent law, including reports on changes in USPTO rules and procedures, recent court decisions, newly filed patent litigation, and recently issued patents.

Chicago, IL About Blog Patent Docs is a weblog authored by patent practitioners, which focuses on biotech / pharma patent law, including reports on changes in USPTO rules and procedures, recent court decisions, newly filed patent litigation, and recently issued patents.

Chicago, IL About Blog Patent Docs is a weblog authored by patent practitioners, which focuses on biotech / pharma patent law, including reports on changes in USPTO rules and procedures, recent court decisions, newly filed patent litigation, and recently issued patents.

As South Africa is currently a non-examining country (there are plans to start examining at least pharma patents), the number of pharma patents granted here are higher than in countries having a similar socio - economic background and in which patents are examined.

Not exact matches

Big biotech and pharma companies are absolutely dependent on being able to successfully innovate by partnering with and acquiring disruptive startups because of the nature of the patent cliff in pharmaceuticals.

More than 25 % of the major blockbuster drugs of the Top 10 pharmas are coming off patent in the next three years.

Now, the innovation pipelines are dry, the pharma companies are peering (or falling) over the patent cliff.

Concerns over these patent expiries, coupled with the recession, caused many investors to flee Big Pharma stocks altogether.

Jazz said in a filing that it did so in response to the overall takeover environment for pharma companies and in light of a patent litigation settlement that allows Hikma Pharmaceuticals to sell a generic version of Xyrem with Jazz receiving royalty payments on those sales.

After internally dividing its slower - growth «established pharma» business from its more innovative patented drugs in 2014, Pfizer recently told analysts that it will decide by the end of 2016 whether to truly split itself up.

ICCR encourages pharma companies to share patents for their life - saving HIV drug formulations through the Medicines Patent Pool as a way to make them more affordable and available where they are needed most.

No. 3: The year of big pharma In the past five years, big cap pharmaceutical stocks have lagged biotech stocks because they've struggled to fill revenue gaps created by the patent cliff.

What I am saying is we need to reevaluate the system that allows Big Pharma to keep reapplying for patent extensions for dubious claims on additional properties of their products, resulting in higher costs.

As patents on existing drugs run out, Big Pharma is turning its attention (back) to the natural world, writes Rob Verkerk

IN TODAY»S biotech industry, start - up companies sprout from every university biology department, looking to hook up with big pharma or agrochemical firms to take their patented, DNA - based ingenuity lucratively to market.

As the pharmaceutical industry's blockbuster drugs fall off the patent cliff, with precious few drugs in the pipeline to replace them, there are signs that big pharma could turn more of its attention to biologically derived medicines.

And a draft executive order on drug pricing, which has not been finalized, includes many policies on pharma's wish list, including extending patents for drugs sold overseas.

There is a need to interact with biotech and pharma, a need to understand intellectual property and patenting — all of this is really now part of the academic career,» says Alving, who adds «many individuals will have careers in academia, but they may have also spent some time in industry.

This program has delivered key outcomes including 15 patents and the licensing of seven discoveries to Pharma and Biotech.

U-M holds a patent on MM - 401 and has licensed it to Ascentage Pharma, a China - based company co-founded by Wang in which the university holds equity.

Perhaps for reasons of self - preservation, he also fails to disclose his close ties to Big Pharma, including his patent on the rotavirus vaccine he co-invented.

Pharma scientiests research amazonian plants and create a synthetic version for pharmaceutical drugs that they can patent and profit from.

It was true that the studies proving the case for patent restoration — for laws that would give pharma additional compensatory patent time — were weak and inconclusive, but the essence of the industry argument struck a nerve with Engman: here again was a case of overregulation hurting the economy of the nation and depriving the consumer of an improved product.

Brian Feroldi: Patent expirations on key drugs have wreaked havoc on many pharma companies» financial statements over the past few years, but few companies have been hit as hard as Pfizer (NYSE: PFE).

Finally, a review of this year's Canadian biotech and pharma licensing trends shows that even facing a patent cliff, pharmas (as licensing payers) still wield a fair amount of bargaining power.

Indeed, one needs to appreciate the very peculiar features prevailing in the pharma sector and the potential conflict between competition law and IPRs, which results from the fact that - as a rule - pharmaceutical firms enjoy patent protection.

The firm was also shortlisted — both nationally and in the northeast — as one of the Patent Contentious Firms of the Year, as well as among the Copyright Northeast Firms of the Year, and the Pharma IP Litigation Firms of the Year.

There are of course some high profile patent lawsuits in this country, for instance in the pharma field.

Our team led advised joint administrators of Redx Pharma plc on the disposal of assets, including patents in the Redx BTK program, for the sum of US$ 40 million.

The recent introduction of generic Lipitor in Canada is one example of the challenges facing pharma companies as current blockbusters come off patent and face generic competition.

Trial counsel for BioChem Pharma in patent infringement litigation involving Epivir ® brand HIV therapy.

This time, however, the source familiar with the patent coalition said that the pharma industry may stay out of the legislative debate — so long as the drug companies feel comfortable the measures are aimed at patent trolls and not pills.

This has been a sticking point for reform because the justification for patents in pharma, where innovation is slow and incredibly expensive, is much different than in tech where innovations are often obsolete in a year or two.

Some are pointing to the fact that David Kappos, the previous director of the Patent Office, was from the tech industry, so the next one has to come from pharma or biotech.

While 2012 has seen far fewer pharma layoffs than in recent years, according to an article for Townhall.com, expiring patents and pricing pressures have many pharma companies concerned.

About Blog Pharma in Brief is written by Norton Rose Fulbright litigation and regulatory lawyers covering topics such as patent and class action disputes, drug advertising & reimbursement, and compliance with Health Canada's governing laws and guidelines.

Global About Blog Stay up to date on case law and developments in IP Law on the pharma industry via Kluwer Patent Blog.

West End, District of Columbia About Blog Follow FiercePharma for pharma industry news on big pharma, FDA decisions, patents, pharmaceutical marketing, generic drugs, and other pharma news.